Tags

Type your tag names separated by a space and hit enter

Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study.
Clin Cancer Res. 1998 Jun; 4(6):1489-97.CC

Abstract

Prostate-specific antigen (PSA) is a valuable tumor marker used for diagnosis and management of prostate cancer. Recently, PSA has been found in various female tissues and body fluids. Female breasts, both normal and abnormal, including cancerous tissues, can produce PSA, and this production is regulated by androgens and progestins. Preliminary data suggested that patients with breast tumors positive for PSA may have better prognosis compared to those with PSA-negative breast tumors. This study examines the prognostic value of PSA in a large cohort study of United States patients. Using a PSA assay that has a lower detection limit of 0.001 ng/ml, we measured PSA in tumor cytosolic extracts of 953 women with primary breast cancer. Other information available for this study included age, follow-up time, survival outcome, tumor size, nodal status, steroid hormone receptor levels, DNA analysis by flow cytometry, and postoperative treatment. The median follow-up time was 73 months. During the follow-up, 200 patients relapsed and 188 died. PSA presence was found to be significantly associated with smaller tumors, tumors with low S-phase fraction, diploid tumors, younger patient age, and tumors with lower cellularity. Survival analysis indicated that the relative risks (RRs) for relapse and death were both significantly lower [RR = 0.67 (P = 0.01) for relapse; RR = 0.72 (P = 0.05) for death] in PSA-positive patients (levels higher than the 30th percentile of PSA values) than in PSA-negative patients. The reduced risks for relapse and death remained statistically significant after other clinical and pathological variables were adjusted in the multivariate analysis [RR = 0.68 (P = 0.02) for relapse; RR = 0.65 (P = 0.02) for death]. Our results suggest that the measurement of PSA in breast tumor extracts provides additional information on the prognosis of patients with primary breast cancer.

Authors+Show Affiliations

Diagnostic Systems Laboratories Inc., Webster, Texas 77598-4217, USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

9626467

Citation

Yu, H, et al. "Prognostic Value of Prostate-specific Antigen for Women With Breast Cancer: a Large United States Cohort Study." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, vol. 4, no. 6, 1998, pp. 1489-97.
Yu H, Levesque MA, Clark GM, et al. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. Clin Cancer Res. 1998;4(6):1489-97.
Yu, H., Levesque, M. A., Clark, G. M., & Diamandis, E. P. (1998). Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 4(6), 1489-97.
Yu H, et al. Prognostic Value of Prostate-specific Antigen for Women With Breast Cancer: a Large United States Cohort Study. Clin Cancer Res. 1998;4(6):1489-97. PubMed PMID: 9626467.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. AU - Yu,H, AU - Levesque,M A, AU - Clark,G M, AU - Diamandis,E P, PY - 1998/6/17/pubmed PY - 1998/6/17/medline PY - 1998/6/17/entrez SP - 1489 EP - 97 JF - Clinical cancer research : an official journal of the American Association for Cancer Research JO - Clin Cancer Res VL - 4 IS - 6 N2 - Prostate-specific antigen (PSA) is a valuable tumor marker used for diagnosis and management of prostate cancer. Recently, PSA has been found in various female tissues and body fluids. Female breasts, both normal and abnormal, including cancerous tissues, can produce PSA, and this production is regulated by androgens and progestins. Preliminary data suggested that patients with breast tumors positive for PSA may have better prognosis compared to those with PSA-negative breast tumors. This study examines the prognostic value of PSA in a large cohort study of United States patients. Using a PSA assay that has a lower detection limit of 0.001 ng/ml, we measured PSA in tumor cytosolic extracts of 953 women with primary breast cancer. Other information available for this study included age, follow-up time, survival outcome, tumor size, nodal status, steroid hormone receptor levels, DNA analysis by flow cytometry, and postoperative treatment. The median follow-up time was 73 months. During the follow-up, 200 patients relapsed and 188 died. PSA presence was found to be significantly associated with smaller tumors, tumors with low S-phase fraction, diploid tumors, younger patient age, and tumors with lower cellularity. Survival analysis indicated that the relative risks (RRs) for relapse and death were both significantly lower [RR = 0.67 (P = 0.01) for relapse; RR = 0.72 (P = 0.05) for death] in PSA-positive patients (levels higher than the 30th percentile of PSA values) than in PSA-negative patients. The reduced risks for relapse and death remained statistically significant after other clinical and pathological variables were adjusted in the multivariate analysis [RR = 0.68 (P = 0.02) for relapse; RR = 0.65 (P = 0.02) for death]. Our results suggest that the measurement of PSA in breast tumor extracts provides additional information on the prognosis of patients with primary breast cancer. SN - 1078-0432 UR - https://www.unboundmedicine.com/medline/citation/9626467/Prognostic_value_of_prostate_specific_antigen_for_women_with_breast_cancer:_a_large_United_States_cohort_study_ L2 - http://clincancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=9626467 DB - PRIME DP - Unbound Medicine ER -